Decline of serum CYFRA21-1 during chemoradiotherapy of NSCLC: A probable predictive factor for tumor response

Tumor Biology

Volumn 32, Issue 4, 2011, Pages 689-695

  Wang, Juan ^a   Zhang, Ning ^b   Li, Baosheng ^a   Wang, Zhongtang ^a   Sun, Hongfu ^a   Yi, Yan ^a   Huang, Wei ^a  

^a SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

^b THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

Author keywords

Chemoradiotherapy; CYFRA21 1; Non small cell lung cancer; Predict

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CISPLATIN; CYTOKERATIN 19 FRAGMENT ANTIGEN 21-1; NAVELBINE; NEURON SPECIFIC ENOLASE; TUMOR ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER REGRESSION; CANCER SIZE; CANCER STAGING; CHEMORADIOTHERAPY; COMPUTER ASSISTED RADIOTHERAPY; CONTROLLED STUDY; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; RADIATION RESPONSE; REFERENCE VALUE; RELIABILITY; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE;

EID: 80052304692     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-011-0169-2     Document Type: Article

References (38)

1. Ihde DC, Bunn PA, Hansen HH. Clinical practice guidelines for the treatment of unresectable non-small cell lung cancer: how useful are they? J Clin Oncol. 1997;8:2996-3018.
2. Gridelli C, Rossi A, Maione P. Treatment of non-small-cell lung cancer: state of the art and development of new biologic agents. Oncogene. 2003;22:6629-38. (Pubitemid 37372343)
3. Ebert W, Muley T. CYFRA 21-1 in the follow-up of inoperable non-small cell lung cancer patients treated with chemotherapy. Anticancer Res. 1999;19:2669-72. (Pubitemid 29392435)
4. van der Gaast A, Kok TC, Kho GS, Blijenberg BG, Splinter TAW. Disease monitoring by tumour markers cyfra 21-1 and TPA in patients with non small cell lung cancer. Eur J Cancer. 1995;31A:1790-3.
5. Werner-Wasik M, Xiao Y, Pequignot E, Curran WJ, Hauck W. Assessment of lung cancer response after nonoperative therapy: tumor diameter, bidimensional product, and volume. A serial CT scan-based study. Int J Radiat Oncol Biol Phys. 2001;51:56-61. (Pubitemid 32758861)
6. Mizuguchi S, Nishiyama N, Iwata T, Nishida T, Izumi N, Tsukioka T, et al. Clinical value of serum cytokeratin 19 fragment and Sialyl-Lewis X in non-small cell lung cancer. Ann Thorac Surg. 2007;83:216-21. (Pubitemid 44917907)
7. Holdenrieder S, Stieber P, Von Pawel J, Raith H, Nagel D, Feldmann K, et al. Early and specific prediction of therapeutic efficacy in non-small cell lung cancer patients by nucleosomal DNA and cytokeratin-19 fragment. Ann NY Acad Sci. 2006;1075:244-57. (Pubitemid 44532791)
8. Mizuguchi S, Inoue K, Iwata T, et al. High serum concentrations of Sialyl Lewis(x) predict multilevel N2 disease in non-small-cell lung cancer. Ann Surg Oncol. 2006;13:1010-8.
9. Moro D, Villemain D, Vuillez JP, Delord CA, Brambilla C. CEA, CYFRA21-1 and SCC in non-small cell lung cancer. Lung Cancer. 1995;13:169-76.
10. Pujol JL, Molinier O, Ebert W, et al. CYFRA 21-1 is a prognostic determinant in non-small-cell lung cancer: results of a metaanalysis in 2063 patients. Br J Cancer. 2004;90:2097-105. (Pubitemid 38869712)
11. Stieber P, Hasholzner U, Bodenmuller H, et al. CYFRA 21-1. A new marker in lung cancer. Cancer. 1993;72:707-13. (Pubitemid 23215254)
12. Sugama Y, Kitamura S, Kawai T, et al. Clinical usefulness of CYFRA assay in diagnosing lung cancer: measurement of serum cytokeratin fragment. Jpn J Cancer Res. 1994;85:1178-84. (Pubitemid 24356092)
13. Brechot JM, Chevret S, Nataf J, et al. Diagnostic and prognostic value of Cyfra21-1 compared with other tumour markers in patients with non-small cell lung cancer: a prospective study of 116 patients. Eur J Cancer. 1997;33:385-91. (Pubitemid 27168063)
14. Gautschi O, Bigosch C, Huegli B, Jermann M, Marx A, Chassé E, et al. Circulating deoxyribonucleic acid as prognostic marker in non-small-cell lung cancer patients undergoing chemotherapy. J Clin Oncol. 2004;22:4157-64. (Pubitemid 41185186)
15. Watine J, Friedberg B, Bouarioua N. Biological variables and stratification of patients with inoperable non-small-cell bronchial cancer: recommendations for future trials. Cancer Radiothér. 2002;6:209-16.
16. de Castro J, Rodríguez MC, Martínez-Zorzano VS, Hernández- Hernández A, Llanillo M, Sánchez-Yagüe J. Erythrocyte and platelet phospholipid fatty acids as markers of advanced non-small cell lung cancer: comparison with serum levels of sialic acid, TPS and Cyfra 21-1. Cancer Investig. 2008;26:407-18. (Pubitemid 351601401)
17. Mizuguchi S, Nishiyama N, Iwata T, Nishida T, Izumi N, Tsukioka T, et al. Serum Sialyl Lewis x and cytokeratin 19 fragment as predictive factors for recurrence in patients with stage I non-small cell lung cancer. Lung Cancer. 2007;58:369-75. (Pubitemid 350051511)
18. Buccheri G, Ferrigno D. Lung tumormarkers of cytokeratin origin: an overview. Lung Cancer. 2001;34 Suppl 2:S65-9. (Pubitemid 33101848)
19. Fischer JR, Lahm H. Validation of molecular and immunological factors with predictive importance in lung cancer. Lung Cancer. 2004;45 Suppl 2:S151-161. (Pubitemid 39488185)
20. Plabani M, Basso D, Navaglia F, De Paoli M, Tommasini A, Cipriani A. Clinical evaluation of seven tumor markers in lung cancer diagnosis: can any combination improbe the results? Br J Cancer. 1995;72:170-3.
21. Schalhorn A, Fuerst H, Stieber P. Tumor markers in lung cancer. J Lab Med. 2001;25:353-61. (Pubitemid 33101220)
22. Ardizzoni A, Cafferata MA, Tiseo M, Filiberti R, Marroni P, Grossi F, et al. Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer. Cancer. 2006;107:2842-9. (Pubitemid 44937038)
23. Nieder C, Andratschke N, Jeremic B, Molls M. Comparison of serum growth factors and tumor markers as prognostic factors for survival in non-small cell lung cancer. Anticancer Res. 2003;23:5117-23. (Pubitemid 38182134)
24. Molina R, Filella X, Augé JM, Fuentes R, Bover I, Rifa J, et al. Tumor markers (CEA, CA125, CYFRA 21-1, SCC and NSE) in patients with non-small cell lung cancer as an aid in histological diagnosis and prognosis. Comparison with the main clinical and pathological prognostic factors. Tumour Biol. 2003;24:209-18. (Pubitemid 37500571)
25. Barlési F, Gimenez C, Torre JP, Doddoli C, Mancini J, Greillier L, et al. Prognostic value of combination of Cyfra 21-1, CEA and NSE in patients with advanced non-small cell lung cancer. Respir Med. 2004;98:357-62. (Pubitemid 38443696)
26. Kulpa J, Wójcik E, Reinfuss M, Kołodziejski L. Treatment of non-small-cell lung cancer: state of the art and development of new biologic agents. Oncogene. 2003;22:6629-38.
27. Ochnio J, Rogińska E, Kwiek S, Rowinska-Zakrzewska E. Wartośćoznaczania poziomu antygenu karcinoembrionalnego w surowicy krwi dla rozpoznania raka płuca, oceny jego rozległości i określenia rokowania u chorych leczonych zachowawczo. Pneumonol Pol. 1984;52:313-9.
28. Nisman B, Lafair J, Heching N, Lyass O, Baras M, Peretz T, et al. Evaluation of tissue polypeptide specific antigen, CYFRA 21-1, and carcinoembryonic antigen in nonsmall cell lung carcinoma. Does the combined use of cytokeratin markers give any additional information? Cancer. 1998;82:1850-9. (Pubitemid 28208639)
29. Shinkai T, Saijo N, Tominaga K, Eguchi K, Shimizu E, Sasaki Y, et al. Serial plasma carcinoembryonic antigen measurement for monitoring patients with advanced lung cancer during chemotherapy. Cancer. 1986;57:1318-23. (Pubitemid 16136747)
30. Buccheri G, Ferrigano D, Sartoris AM, Violante B, Vola F, Curcio A. Tumor markers in bronchogenic carcinoma. Superiority of tissue polypeptide antigen to carcinoembryonic antigen and carbohydrate antigenic determinant 19-9. Cancer. 1987;60:42-50. (Pubitemid 17083549)
31. Buccheri G, Ferrigno D. Prognostic factors in lung cancer: tables and comments. Eur Respir J. 1994;7:1350-64. (Pubitemid 24235056)
32. Lai R, Hsu H, Lu JY, Ger LP, Lai NS. CYFRA21-1 enzymelinked immunosorbent assay. Chest. 1996;109:995-1000.
33. Sugama Y, Kitamura S, Kawai T, Ohkubo A, Hasegawa S, Kuriyama T, et al. Clinical usefulness of CYFRA assay in diagnosing lung cancer: measurement of serum cytokeratin fragment. Jpn J Cancer Res. 1994;85:1178-84. (Pubitemid 24356092)
34. Bréchot JM, Chevret S, Nataf J, Le Gall C, Frétault J, Rochemaure J, et al. Diagnostic and prognostic value of Cyfra21-1 compared with other tumourmarkers in patients with non-small cell lung cancer: a prospective study. Eur J Cancer. 1997;33:385-91. (Pubitemid 27168063)
35. Bremnes RM, Sirera R, Camps C. Circulating tumour-derived DNA and RNA markers in blood: a tool for early detection, diagnostics, and follow-up? Lung Cancer. 2005;49:1-12. (Pubitemid 40798088)
36. Vollmer RT, Govindan R, Graziano SL, Gamble G, Garst J, Kelley MJ. Christenson RH Serum CYFRA 21-1 in advanced stage nonsmall cell lung cancer: an early measure of response. Clin Cancer Res. 2003;9:1728-33. (Pubitemid 36554597)
37. Holdenrieder S, Stieber P, von Pawel J, Raith H, Nagel D, Feldmann K, et al. Circulating nucleosomes predict the response to chemotherapy in patients with advanced non-small cell lung cancer. Clin Cancer Res. 2004;10:5981-7. (Pubitemid 39287502)
38. Stieber P, von Pawel J, Raith H, Nagel D, Feldmann K, Seidel D. Circulating nucleosomes predict the response to chemotherapy in patients with advanced non-small cell lung cancer. Clin Cancer Res. 2004;10:5981-7. (Pubitemid 39287502)